Devicor Medical Products and Endomagnetics Ltd. have announced that Devicor Medical Products will be the exclusive distributor of Endomag’s Sentimag, magnetic surgical guidance system, in the United States and Canada. This technology provides a new standard of care for clinicians and breast cancer patients during surgical procedures.
This agreement greatly expands cancer patients’ access to care as the Sentimag system can be used by all hospitals by eliminating the need for radioactive tracers. The Sentimag system and its implantable magnetic seed, Magseed, guide surgeons to cancerous lesions easily and do not require the use of traditional surgical needle wires or radioactive seeds. Similarly, the Sentimag system and its injectable iron solution, Sienna, is a replacement for the radioactive tracer and blue dye used in sentinel lymph node biopsies.
“We are very excited to be the exclusive distributor of the Sentimag system in the United States and Canada,” said Alain de Lambilly, President of Leica Biosystems Tissue Acquisition Solutions business. “The Sentimag system fits in perfectly with our product portfolio and aligns with our mission of advancing cancer diagnostics.”
The agreement includes the Sentimag system, Magseed and Sienna in both the United States and Canada, pending regulatory approval within those markets. The Sentimag system is approved in the U.S. and received its CE mark approval in 2010 and has already been used in over 14,000 breast care procedures across Europe.
